Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03155009
What this trial is testing

The Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 44
Testing effectiveness (Phase 2)Looking for participantsNCT06947694
What this trial is testing

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

Who this might be right for
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing 427
Not applicableLooking for participantsNCT05724004
What this trial is testing

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

Who this might be right for
Radiotherapy Side EffectNon-small Cell Lung CancerALK Gene Mutation
Karolinska University Hospital 70
Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Testing effectiveness (Phase 2)Looking for participantsNCT07415005
What this trial is testing

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 30
Not applicableStudy completedNCT01620853
What this trial is testing

Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Applied Spectral Imaging Ltd. 1
Not applicableLooking for participantsNCT06862869
What this trial is testing

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 800
Post-approval studies (Phase 4)Study completedNCT04362072
What this trial is testing

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
CarcinomaNon-Small-Cell Lung
Pfizer 71
Testing effectiveness (Phase 2)Ended earlyNCT02513667
What this trial is testing

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 14
Large-scale testing (Phase 3)Study completedNCT03596866
What this trial is testing

Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Who this might be right for
ALK+ Advanced NSCLC
Takeda 248
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Early research (Phase 1)Looking for participantsNCT07617337
What this trial is testing

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Chugai Pharmaceutical 102
Not applicableEnrolling By InvitationNCT06876675
What this trial is testing

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerHyperlipidemia
Peking University Third Hospital 167
Large-scale testing (Phase 3)Study completedNCT01828099
What this trial is testing

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750704
What this trial is testing

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 153
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07235306
What this trial is testing

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

Who this might be right for
NSCLC Stage IIIEnsartinibChemoradiotherapy+1 more
Shanghai Pulmonary Hospital, Shanghai, China 45
Not applicableLooking for participantsNCT03042221
What this trial is testing

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Who this might be right for
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more
University of Colorado, Denver 100
Not applicableLooking for participantsNCT06361589
What this trial is testing

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Who this might be right for
ALK-positive Non-small Cell Lung CancerReal World Study
Sichuan Cancer Hospital and Research Institute 200
Testing effectiveness (Phase 2)Ended earlyNCT04139317
What this trial is testing

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 76
Next Page